There has not been a major change in how we treat these cancers for decades
For half a century, small cell neuroendocrine cancers have defied medicine's best efforts, leaving patients in 2025 with survival odds little better than those in 1975. Now, researchers at UCLA have found that these tumors carry within their own genetic losses the seed of a potential vulnerability — a dependency on a protein called E2F3 that, when removed, causes the cancer to falter and collapse. The discovery, rooted in years of painstaking laboratory work, points toward existing FDA-approved drugs as possible weapons in a fight that has long seemed unwinnable.
- Small cell neuroendocrine cancers have remained essentially untreatable for fifty years, spreading fast and resisting nearly every targeted therapy developed against them.
- UCLA researchers discovered that when these tumors lose the RB gene — a common occurrence — they become critically dependent on a single protein, E2F3, creating an exploitable weakness the cancer cannot easily escape.
- A massive CRISPR screen across nearly 1,400 genes confirmed that this E2F3 dependency is not limited to one cancer type but appears consistently across small cell tumors in the lungs, prostate, and ovaries.
- When E2F3 was reduced in lab models, tumor growth halted, cells lost their ability to cluster, and some died — a phenomenon known as synthetic lethality that turns the cancer's own genetic damage against it.
- The path to patients may be shorter than expected: existing FDA-approved autoimmune drugs that lower E2F3 levels indirectly are already on pharmacy shelves, potentially compressing the timeline to clinical trials.
Small cell neuroendocrine cancers are among oncology's most stubborn adversaries — fast-growing, early-spreading, and largely unchanged in their resistance to treatment for more than fifty years. A patient diagnosed in 1975 faced roughly the same odds as one diagnosed today. That grim stasis is what makes a discovery from UCLA researcher Dr. Owen Witte and his team so significant.
The key insight involves a gene called RB, which normally acts as a brake on cell growth. These cancers frequently lose RB entirely, allowing cells to multiply unchecked. But that loss, the UCLA team found, creates an unexpected vulnerability: without RB, the cancer becomes critically dependent on a protein called E2F3 to survive. Eliminate E2F3, and the tumor collapses — an example of synthetic lethality, where two genetic absences together prove fatal in ways that neither would alone.
The finding emerged from more than a decade of laboratory development. Witte's team built sophisticated tumor models using human prostate cells engineered with multiple cancer-causing mutations, grown into three-dimensional organoids and implanted in mice. From there, a CRISPR screen of nearly 1,400 genes identified which were essential to the cancer's survival. One result stood out clearly: small cell cancers from the lungs, prostate, and ovaries all shared the same strong dependence on E2F3. Reducing E2F3 levels stopped tumor growth and, in some cases, killed the cells outright.
The most immediate practical implication involves drugs that already exist. No direct E2F3 blocker is currently available, but the team found that inhibiting an enzyme called DHODH lowers E2F3 levels and slows tumor growth. Crucially, DHODH inhibitors — leflunomide and teriflunomide — are already FDA-approved for autoimmune conditions. First author Dr. Evan Abt noted that understanding the cancer's dependency on E2F3 opens strategies that could reach patients far more quickly than developing an entirely new drug. For a disease that has resisted progress for half a century, that possibility represents a genuine turning point.
Small cell neuroendocrine cancers are among the cruelest diseases in oncology. They grow fast, spread early, and have resisted meaningful progress for half a century. A patient diagnosed with one of these tumors in 1975 had roughly the same survival odds as one diagnosed in 2025. That stasis—that stubborn refusal of medicine to improve—is what makes a UCLA discovery published this summer worth attention.
Researchers led by Dr. Owen Witte have identified what amounts to a hidden pressure point in these cancers. The tumors often lose a gene called RB, which normally acts as a brake on cell growth. Without it, cancer cells multiply rapidly and shrug off most targeted drugs. But the loss of RB, it turns out, creates an unexpected dependency. These cells become critically reliant on a protein called E2F3 to stay alive. Remove E2F3, and the cancer collapses—a phenomenon scientists call synthetic lethality, where two genetic losses together prove fatal even though either one alone might be survivable.
The discovery emerged from years of painstaking laboratory work. Witte's team engineered human prostate cells with five major cancer-causing mutations, including the loss of both RB and another gene called TP53. They grew these cells into three-dimensional structures called organoids, then implanted them into mice to create tumors that closely mimic what happens in human patients. This was not quick work. It took more than a decade of development to build models realistic enough to be useful.
Once they had those models, the researchers performed a massive genetic screen using CRISPR technology, examining thousands of genes to identify which ones the cancer cells absolutely needed to survive. Nearly 1,400 genes emerged as essential. But one finding stood out: small cell cancers from different organs—lung, prostate, ovary—all showed the same strong dependence on E2F3. When the team reduced E2F3 levels in RB-deficient cancer cells, tumor growth stopped. Cells could no longer cluster together. In some cases, they died outright.
Witte, who first encountered these cancers as a medical student more than fifty years ago, understands the weight of that stasis. "There has not been a major change in how we treat these cancers for decades," he said. The new finding breaks that pattern. It points toward an entirely different approach to treatment—one that exploits the cancer's own dependencies rather than attacking it head-on.
The most immediate practical implication is striking. No drug currently exists to block E2F3 directly. But the UCLA team found that inhibiting an enzyme called DHODH—which helps produce the building blocks cells need to make DNA—lowers E2F3 levels and slows tumor growth. And here is where the work intersects with real patients: DHODH inhibitors already exist. Leflunomide and teriflunomide are FDA-approved medications used to treat autoimmune diseases. They sit on pharmacy shelves. The question now is whether they might be repurposed to fight these cancers.
Dr. Evan Abt, the study's first author, framed the opportunity plainly: "By understanding how these cancers depend on E2F3, we can start to think about strategies that might work much more quickly in patients." The research remains early. Laboratory models are not patients. But the pathway from bench to bedside has suddenly become clearer. Existing drugs, already proven safe in other contexts, might be tested in clinical trials for small cell cancer within a timeframe that would have seemed impossible just months ago. For a disease that has resisted progress for fifty years, that represents a genuine shift.
Citas Notables
Discovering a vulnerability like this opens the door to thinking about entirely new treatment strategies, especially important because there has not been a major change in how we treat these cancers for decades.— Dr. Owen Witte, UCLA study senior author
By understanding how these cancers depend on E2F3, we can start to think about strategies that might work much more quickly in patients.— Dr. Evan Abt, first author of the study
La Conversación del Hearth Otra perspectiva de la historia
Why has this particular cancer been so hard to treat for so long?
Small cell neuroendocrine cancers grow and spread aggressively, and they lose the RB gene early—the very gene that normally keeps cell growth in check. Once RB is gone, the cancer becomes resistant to most targeted therapies. It's like removing the brake and then finding that conventional tools don't work on a runaway car.
So the E2F3 dependency—is that something unique to these cancers, or do other cancers have similar hidden dependencies?
That's the key insight here. The UCLA team found that E2F3 dependency appears across small cell cancers in different organs. It's a shared vulnerability, which suggests it might be a fundamental weakness in how these particular cancers survive when RB is missing.
And the synthetic lethality concept—that's saying the cancer can live without RB, but dies without both RB and E2F3?
Exactly. The cancer has adapted to survive without RB. But that adaptation creates a new fragility. The cancer cell becomes dependent on E2F3 to compensate. Remove both, and the cell has no way forward.
Why did it take so long to discover this if these cancers have been around for decades?
The researchers needed realistic laboratory models first. Without them, you're essentially guessing in the dark. Building those models took over a decade of work. Once they had them, they could run the genetic screens that revealed the E2F3 dependency.
And the drug angle—leflunomide and teriflunomide are already approved. Does that mean trials could start soon?
It's possible, but there are steps. The research is still early. What's promising is that these drugs are already known to be safe in humans, which could accelerate the pathway to testing them in cancer patients. But that's still a process.
What does this mean for someone diagnosed with small cell cancer right now?
Right now, it doesn't change their immediate treatment options. But it opens a door. For the first time in fifty years, there's a concrete new direction for research and drug development. That matters for future patients, and it matters for the field's momentum.